Castle Biosciences Shares Are Trading Lower After the Company Reported Preliminary FY24 Financial Results.

BenzingaJan 13 23:24

Castle Biosciences | 8-K: Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

SECJan 13 20:27 · Announcements

BTIG Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $40

Futu NewsJan 13 18:32 · Ratings

Castle Biosciences Reports Preliminary 2024 Results: Expects $320M-$330M In Annual Revenue (+50% YoY), 96,071 Total Tests Delivered (+36% YoY), And $293M In Cash And Investments

BenzingaJan 13 16:09

Castle Biosciences Positioned for Growth After Novitas Resolution and Focus on Core Franchises

TipRanksJan 13 13:55

Express News | Castle Biosciences Inc - 2024 Revenue Expected to Exceed $320-330 Million, 50% Growth Over 2023

BreakingsJan 13 07:00